Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation

NCT07541469 is registered in ClinicalTrials.gov with Madrigal Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07541469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07541469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Phase
Observational
Overall status
Recruiting
Start date
March 4, 2026
Completion date
April 8, 2030
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mash - metabolic dysfunction-associated steatohepatitis